Guangzhou Wondfo Biotech Co.,Ltd
Shenzhen Stock ExchangeTotal Valuation
Guangzhou Wondfo Biotech Co.,Ltd carries a market capitalization of 8.03B, placing it among publicly traded companies globally. Its enterprise value stands at 9.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.03B |
| Enterprise Value | 9.43B |
Share Statistics
Guangzhou Wondfo Biotech Co.,Ltd currently has 481.42M shares outstanding.
| Shares Outstanding | 481.42M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Guangzhou Wondfo Biotech Co.,Ltd trades at a trailing price-to-earnings ratio of 26.21. The price-to-sales ratio is 3.79, and the price-to-book ratio stands at 2.57.
| PE Ratio | 26.21 |
| PS Ratio | 3.79 |
| PB Ratio | 2.57 |
| P/TBV Ratio | 1.98 |
| P/FCF Ratio | 42.03 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Guangzhou Wondfo Biotech Co.,Ltd trades at an EV/EBITDA multiple of 20.53 and an EV/FCF ratio of 34.32. The EV/Sales ratio of 3.45 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 20.53 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.45 |
| EV / EBITDA | 20.53 |
| EV / EBIT | 20.53 |
| EV / FCF | 34.32 |
Financial Position
Guangzhou Wondfo Biotech Co.,Ltd maintains a current ratio of 5.72, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 10.72, indicating elevated leverage, while an interest coverage ratio of 14.99 demonstrates strong ability to service its debt obligations.
| Current Ratio | 5.72 |
| Quick Ratio | 2.71 |
| Debt / Equity | 10.72 |
| Debt / EBITDA | 1.31 |
| Interest Coverage | 14.99 |
Financial Efficiency
Guangzhou Wondfo Biotech Co.,Ltd posts a return on equity of 10.09 and a return on invested capital of 6.90.
| Return on Equity (ROE) | 10.09 |
| Return on Assets (ROA) | 5.82 |
| Return on Invested Capital (ROIC) | 6.90 |
| Return on Capital Employed (ROCE) | 9.13 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.63 |
Taxes
Over the trailing twelve months, Guangzhou Wondfo Biotech Co.,Ltd has paid 31.78M in income taxes, reflecting an effective tax rate of 7.41.
| Income Tax | 31.78M |
| Effective Tax Rate | 7.41 |
Stock Price Statistics
Guangzhou Wondfo Biotech Co.,Ltd's stock has declined approximately -19.972% over the past 52 weeks. The 50-day moving average sits at 18.40, while the 200-day moving average is 19.91.
| Beta (5Y) | N/A |
| 52-Week Price Change | -19.972% |
| 50-Day Moving Average | 18.40 |
| 200-Day Moving Average | 19.91 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Guangzhou Wondfo Biotech Co.,Ltd generated 2.74B in revenue and converted that into 395.03M in net income, yielding earnings per share of 0.82. EBITDA reached 459.19M, while operating income came in at 459.19M.
| Revenue | 2.74B |
| Gross Profit | 1.74B |
| Operating Income | 459.19M |
| Pretax Income | 428.89M |
| Net Income | 395.03M |
| EBITDA | 459.19M |
| EBIT | 459.19M |
| Earnings Per Share (EPS) | 0.82 |
Balance Sheet
Guangzhou Wondfo Biotech Co.,Ltd holds 1.61B in cash and equivalents against 603.30M in total debt, resulting in a net debt position of 242.97M. Total book value stands at 4.02B, with working capital of 2.79B providing operational flexibility.
| Cash & Cash Equivalents | 1.61B |
| Total Debt | 603.30M |
| Net Debt | 242.97M |
| Equity (Book Value) | 4.02B |
| Book Value Per Share | 8.29 |
| Working Capital | 2.79B |
Cash Flow
After subtracting -246.34M in capital expenditures, free cash flow totaled -246.34M - equivalent to -0.51 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -246.34M |
| Free Cash Flow | -246.34M |
| FCF Per Share | -0.51 |
Margins
Guangzhou Wondfo Biotech Co.,Ltd operates with a gross margin of 63.45, reflecting its pricing power and cost economics. The operating margin of 16.79 and net profit margin of 14.44 provide insight into operational efficiency.
| Gross Margin | 63.45 |
| Operating Margin | 16.79 |
| Pretax Margin | 15.68 |
| Profit Margin | 14.44 |
| EBITDA Margin | 16.79 |
Dividends & Yields
The company's payout ratio of 2.10 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.02 |
| Dividend Yield | N/A |
| Payout Ratio | 2.10 |
| Shareholder Yield | 0.81 |
| FCF Yield | 2.38 |
Stock Splits
Guangzhou Wondfo Biotech Co.,Ltd's most recent stock split took place on May 26, 2021 with a 10:13 split ratio.
| Last Split Date | 5/26/2021 |
| Split Ratio | 10:13 |
Scores
Guangzhou Wondfo Biotech Co.,Ltd posts an Altman Z-Score of 6.81, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.81 |